STOCK TITAN

Gilead Sciences: Living with a Rare Blood Cancer: Marion’s Story

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

NORTHAMPTON, MA / ACCESSWIRE / June 7, 2023 / Marion grew up very healthy, never even getting colds or the flu - but that changed as she got older.

In her late 50s, Marion's doctor found a cancerous wart that required an intense six weeks of radiation therapy, coupled with chemotherapy. Then nearly five years later, she was diagnosed with myelodysplastic syndrome (MDS), a rare form of blood cancer that often occurs in people previously treated with radiation or chemotherapy.

A stem cell transplant is usually key to surviving MDS, but due to Marion's age and chronic conditions, she wasn't a good candidate for a transplant. Instead, her hematologist put her on a medication and she responded well.

Today Marion visits her doctor every four weeks for blood testing and has been treatment-free for more than 18 months.

"I don't look back," she says of her experience. "The disease does not define me. I am still me."

Originally published by Gilead Sciences

Gilead Sciences, Wednesday, June 7, 2023, Press release picture

View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

Contact Info:
Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: info@3blmedia.com

SOURCE: Gilead Sciences



View source version on accesswire.com:
https://www.accesswire.com/759805/Gilead-Sciences-Living-with-a-Rare-Blood-Cancer-Marions-Story

Gilead Sciences Inc

NASDAQ:GILD

GILD Rankings

GILD Latest News

GILD Stock Data

110.16B
1.24B
0.12%
88.41%
1.42%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States of America
FOSTER CITY